Scientists are experimenting with an antibody treatment for Covid patients that can prevent people who are exposed to the virus from getting sick, which may save lives.
Researchers at University College Hospital London (UCLH) are studying the possibility that the antibody therapy developed by AstraZeneca can provide immunity to people in need.
This therapy is part of the Storm Chaser project, and once one person becomes ill, it can be used to prevent other people from developing Covid-19 symptoms.
At the same time, the second trial conducted by UCLH called Provent will investigate whether this treatment can be used in people with a poor immune system and a high risk of the virus.
Professor Stephen Powis, National Medical Director of NHS England, said: “The NHS continues to make outstanding contributions in its global efforts to combat Covid-1
“These two clinical trials are an important addition to testing new therapies, because antibody therapy may provide alternative options for patient groups that cannot benefit from vaccines, such as immunocompromised patients.”
Since the study entered the third phase of the trial on December 2, researchers have so far injected 10 people into its new vaccine research center as part of Storm Chaser, with the goal of testing new therapies on 1,125 people worldwide, including Medical staff, students in shared accommodation, and patients who have recently been in contact.
Those long-term care workers, military and workers including factory employees will also be included in the trial.
Dr. Catherine Houlihan, a UCLH virologist who led the Storm Chaser trial, said: “We know this combination of antibodies can neutralize the virus, so we hope that this treatment given by injection can immediately prevent Covid-19 of the people who have been exposed- It is too late to provide vaccines.”
At the same time, in the Provent trial, the elderly and long-term care workers will be recruited, as well as people with diseases such as cancer and HIV.
Dr. Nicky Longley, a UCLH infectious disease consultant who leads the University’s Provent department, said: “We want to assure anyone who may not be able to use the vaccine that we can provide a protective alternative.”
Agency’s Supplementary Report